Replay available

IRIDEX (NASDAQ:IRIX) Q4 2020 Earnings Call

IRIDEX (NASDAQ:IRIX) Q4 2020 earnings call, held 2021-03-22. Watch the replay and read the transcript on 6ix.

Mon, March 22, 2021 at 5:00 PMendedReplay
IRIDEX (NASDAQ:IRIX) Q4 2020 Earnings Call
Company
IRIDEX Corporation (NASDAQ:IRIX)
Period
Q4 2020 earnings call
Date
Mon, Mar 22, 2021, 5:00 PM ET
Replay
Watch the replay on this page · 24 min
Results news release
Iridex Announces Fourth Quarter and Full Year 2020 Financial Results · Mon, Mar 22, 2021

On 6ix: 6ix.com/event/iridex-corporation-irix-q4-2020-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Ladies and gentlemen, thank you for standing by, and welcome to the Eridex Q4 and full year 2020 conference call. At this time, all participants are on listen-only mode.

0:09 After the speaker's presentation, there will be a question and answer session. To ask a question at that time, please press star then 1 when you touch the telephone. As a reminder, today's conference call is being recorded. I will now turn the conference over to your host, Ms. Leigh Salvo, with investor relations. Can you let me in?

0:26 Thank you, and thank you all for participating in today's call. Joining me are David Bruce, Chief Executive Officer, and Fwad Ahmad, Interim Chief Financial Officer. Earlier today, Iridex released financial results for the quarter and year-ended January 2, 2021. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities law, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical fact, including but not limited to statements concerning our strategic goals and priorities, product development matters, sales trends, and the markets in which we operate.

1:15 All forward-looking statements are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ Thank you for listening. March 22nd, 2021. With that, I'll turn the call over to Dave.

2:01 Thank you, Leigh, and good afternoon, everyone. Thanks for joining us. On today's call, I'll provide a brief review of Iridex's 2020 progress, where our business stands today, and our fourth quarter and full year results. Then I'll touch on our continuing growth initiatives and outlook for 2021. After that, Fuad Ahmed will provide additional color on our financial results for the quarter and the year, and then we'll open it up for calls and questions. So clearly, 2020 was an extraordinary and difficult year for many companies. At Iridex, we saw our second quarter revenues fall by 40%, but over the course of the remainder of the year, with focus from the entire Iridex team, We adjusted how we operate and sell and ended 2020 delivering one of our strongest quarters in years. In addition, we achieved several important milestones, including launching improved products and enhancing our market position.

3:03 And we exited the year with solid momentum that will help drive several exciting catalysts in 2021 and beyond. I'm pleased to report that Iridex had a great fourth quarter. Despite continuing COVID impacts, year-over-year revenue increased by 5% to $12.3 million, a multi-year quarterly high, plus growth margin improved by 4 percentage points, while operating expenses were reduced by 9%, resulting in nearly break-even net income. Returning to highlights of the progress in 2020, The year was, of course, dominated by managing and responding to challenges created by the pandemic. However, we also continued to execute on our longer-term strategic objectives.

3:55 First, we implemented structural changes to reduce operating costs and preserve cash to extend our financial runway, and the success of these measures allowed us to limit cash usage to only $1 million for all of 2020. We finished the year with $11.6 million in cash. Second, we adjusted our sales and marketing processes to improve market awareness and expand adoption of our non-incisional micropulse transcleral laser therapy, or TLT, engaging new customers and re-engaging our significant install base. We began the year launching our revised micropulse P3 probe, then mid-year successfully shifted to virtual and web-based sales activities supporting customers. Although mid-year procedure volume declined significantly starting in April as offices and surgery center closures were strictest, we strongly recovered US glaucoma probe volumes in Q3 and Q4, both exceeding 2019 pre-COVID levels.

5:01 And third, we continued rolling out product enhancements that strengthened our competitiveness and improved gross margins. We updated our Texcel scanning laser module, launched both an updated and a new LIO delivery device and made substantial progress on our new lower cost laser platform receiving FDA clearance and readying the first of the family for launch in 2021. Our progress on these initiatives during the challenging environment in 2020 makes us very confident for 2021. I'd like to take the next few minutes and share some additional highlights from the fourth quarter. Topline revenue in the quarter exceeded the pre-COVID revenue in the prior year period, improving 5% to $12.3 million.

5:49 Adoption of our cyclo G6 probes reached a record quarter in the U.S. with 8% growth over 2019. Outside the U.S., continued impact from COVID restrictions caused small reductions in probe usage. In the fourth quarter, we announced that our micropulse TLT has been included in the European Glaucoma Society's Terminology and Guidelines for Glaucoma. These new guidelines were presented at the Annual Society Meeting this past December. In addition, nine new micropulse TLT studies were presented, exemplifying the continued global expansion and potential for this treatment. We're very encouraged by the results in the fourth quarter from our retina business as well. which had been severely impacted in the third quarter down 23% versus the prior year. In the fourth quarter, this segment rebounded strongly, posting 11% year-over-year growth.

6:51 We expect this strength to continue in 2021, particularly as we execute the TopCon collaboration elements. And finally, we're pleased with our success in fourth quarter managing our capital resources. Similar to the third quarter, our web-based sales and marketing activities enable us to limit operating expenses while at the same time exceeding revenue from the prior year. I'd like to briefly highlight our continued progress in product development, circling back to the launch of our new laser indirect ophthalmoscope, the LAO Plus, in the third quarter. The positive feedback we received from our users following that launch has translated to adoption and strong order flow in the fourth quarter.

7:37 We expect this enthusiasm to continue in 21 as the ophthalmic business landscape recovers from the deferrals and cancellations that resulted from COVID. We also have our new laser system platform well underway with the 810 system launching soon and the 532 and 577 frequency lasers expected later in the year. In addition, with the acquisition of the Pascal scanning laser line, we plan to combine the key features from Pascal and our Micropulse and Taxel products into a single leading platform. Lastly, let me recap the exciting strategic collaboration with Topcon that we announced just a few weeks ago via press release and a conference call, both of which can be found on the investor section of our website.

8:28 Topcon is a Japanese-based manufacturer and distributor with approximately $1.3 billion annual revenue in 2019, including $430 million from its global eye care business. This new collaboration enhances our value proposition on three fronts. First, it provides significant additional capital to drive new growth initiatives in retina and glaucoma. Second, it expands our distribution network throughout Asia Pacific and key EMEA regions, Europe, Middle East, and Africa. And third, it increases revenue and scale by combining Topcon's Pascal line with Iridex's Micropulse and TechCell products, creating a leader in technology and in market share for retinal scanning laser products.

9:19 The transaction is expected to net $19.5 million in cash to Iridex, and this allows us to fund strategic growth initiatives such as expanded sales teams, clinical studies and market development programs all designed to drive faster market adoption of our glaucoma therapy products. As part of the collaboration, Topcon will assume exclusive distribution rights in Asia Pacific and key EMEA markets for both our retina and glaucoma products. In total, this will account for approximately 60% of our international revenue and the remaining portion will continue to be sold through our current distributor network. In assuming exclusive distribution rights, both Iridex and Topcon will benefit from a broader offering of diagnostic and treatment products for both glaucoma and retina customers. And finally, combining the acquired Pascal product line with Microsoft, Micropulse and Texel platform products will result in a leading market share in the marketplace, as well as a greater scale to generate design, manufacturing, and marketing efficiencies.

10:33 So in summary, we believe our fourth quarter results demonstrate the momentum created by the hard work of the Aerodex team over the past 18 months. We've seen sales growth in retina thanks to new products, and we've seen increased market uptake of our unique micropulse TLC glaucoma treatment, all despite significant COVID headwinds. This gives us the confidence to increase our investments to grow both retina and glaucoma segments as we anticipate the ophthalmic market returning to normal as the year progresses. With that, I'd like to turn the call over to Fuad Ahmed.

11:14 Thank you, Dave, and good afternoon, everyone. I will now go over our financial performance for the fourth quarter of fiscal 2020, starting with revenue. Total revenue for the fourth quarter was $12.3 million, up 5% from $11.8 million in the fourth quarter of last year, and up 40% from $8.8 million sequentially. We sold 13,500 cyclo-G6 probes in the quarter, same volume sold in the fourth quarter of last year, but up 18% over the 11,400 probes sold in Q3. We saw probes volumes approaching the pre-pandemic levels with pricing levels at or above last year. We sold 57 cyclo-G6 systems in the quarter compared to 107 in the prior year period and 37 sold in Q3 of this year.

12:08 The reduction compared to the fourth quarter of fiscal 2019 was primarily due to the COVID-related capital purchase deferrals by customers. However, Thank you for joining us today. Although down 5% compared to the fourth quarter of 2019 because of lower system sales, it was 25% improvement from $2.8 million in Q3 of 2020.

12:56 Our retina revenue improved significantly in the fourth quarter and posted an increase of 11% compared to the prior year period and 56% compared to the third quarter. To recap, Our retina products include lasers, various delivery devices, which we define as capital equipment, and endoprobes, which are a single-use per procedure product. Results in our retina product line were helped by the release of improved products and capturing previously deferred capital equipment purchases by customers in light of improving COVID-related outlook, both in the U.S. and OUS. Other revenue, which includes royalties, services, and other legacy products, increased 3% to $1.9 million in the fourth quarter of 2020 compared to 2019.

13:50 Gross margin in the fourth quarter of 2020 was up 420 basis points to 45.4% compared to 41.2% in the fourth quarter of 2019. Gross margin improved significantly as a result of solid pricing discipline and improvement in manufacturing cost structure. As previously reported, gross margin enhancements have been and will continue to be an area of focus for the company. Operating expenses for the fourth quarter of fiscal 2020 were $5.9 million compared to $6.5 million in the same period of the prior year, a 9% decrease. The decrease was a result of our continuing efforts to reduce our operating expenses both in response to the pandemic and a careful reassessment of our cost structure during fiscal 2020.

14:43 As a result of meaningful gross margin and operating expense improvements, we reduced our net loss in the fourth quarter to 179,000 or a net loss of one cent per share, an improvement of nearly 1.4 million or 10 cents per share from last year. We ended the year with cash and cash equivalents of $11.6 million, down approximately $1 million from the end of 2019, inclusive of the PPP loan. We are very pleased with our year-end liquidity, despite an overall decline in 2020 revenue. Our recently announced transaction with Topcon further bolsters our liquidity and gives us additional resources to accelerate our growth plans while retaining our focus on prudent cost structure and revenue growth.

15:35 which brings us to guidance. Given the continuing variability in product demand due to COVID, combined with variability introduced by TopCon collaboration affecting revenue recognition, sales transition effects, and integration costs with the Pascal product line, IRDX cannot provide a meaningful financial guidance for 2020 at this time. With that, Dave and I would like to turn the call over to the operator for questions. Operator? Thank you. Again, ladies and gentlemen, if you'd like to ask a question, please press star then one on your touchtone telephone. One moment, please. Our first question comes from John Block of People. Your line is open.

16:20 Great. Thanks, guys. Good afternoon, Dave and Claude. Hope all is well. First question, I'll just pick up one where you left off. I know you're not going to give explicit details. 2021 guidance, but it seems like the business has good momentum. You exited 4Q in a very strong fashion. When we just think about, you know, sequentially the 4Q to 1Q step down that Iridex has usually experienced, it's been a little bit bouncy, but maybe 10% or so, a million, a million and change. Is that the right neighborhood to be in, or are there any sort of, you know, maybe – Gold Post that you can put up when we think about how to think about that 4Q20 to 1Q21 sequential move.

17:04 Hey, John. It's Dave. Thanks for joining the call this afternoon. Typically, we do see a reduction from the fourth quarter to the first quarter. The fourth quarter is often a big capital equipment purchase quarter. Probes also, though, experience some reduction into the first quarter as you know health plan deductibles are met at the end of the quarter and people aren't as aggressive in going to get procedures early on. So that's the typical profile. We did say we're seeing continued momentum from capital equipment success in the fourth quarter and I think relatively we can you know you can anticipate that as well and then it's It's always backloaded on quarters for capital equipment, so we do have a couple weeks left in this quarter, and that can introduce some variability, but typically we're comfortable with the more standard step function. Now, that said, we closed the transaction with Topcon, and we are now manufacturing the Pascal product line and anticipate some revenue from that product line added into the quarter as well.

18:22 Okay, great. That was actually going to be one of my questions, but you clarified that. So think about maybe a couple quarter, sorry, a couple week contribution from Pascal specific to your 1 to 21 results. All right, and then I'll just pivot. I'll stay within the P&L. The gross margin I thought was certainly, you know, a highlight in the quarter, mid 40% range. I think one of the stronger results in several quarters in some time. How do we think about the gross margin cadence? If I go back to the announcement with TopCon, I think you said expect some maybe pressure earlier on in the year and then strengthening throughout 2021. So do we think about that mid-40 range, maybe taking a step back in the first half, but maybe still all in for the full year, the mid-40s is a good place to be?

19:05 Yeah, I mean, I think that's generally the right way to think about it. I think as we talked about on our call when we announced the TopCon transaction, The first quarter or so is going to be somewhat choppy given the distribution move over to Topcon as well as the integration costs associated with taking on the Pascal product line. So we expect there will be some compression on the overall corporate margin. And then as those integration costs are traded away, I think we feel like we'll get back to the Leigh Salvo, Leigh Salvo So those will obviously continue from that perspective, but there's some overhang from the transaction side.

20:18 And I'll just add to that, John, that capital equipment is typically at a lower gross margin than disposables. And as we've added a chunk of capital equipment revenue, on average, that's a higher percent of our revenue. So that just by itself will pull down a bit the total average gross margins for the company. that's offset by obviously higher revenue that comes in as well. And as we continue to grow the pro business, that should drive gross margins up. And as you said earlier, it's going to take a quarter or a couple quarters to clean up the integration and get the overhead in line as well as operating costs.

21:06 We're just starting to integrate and we'll have some opportunities to to have a better view of where we can go as we operate for a period here.

21:16 Got it. Maybe last one or two for me. I mean, you know, Dave, you mentioned we saw in the press release a while ago, but MicroPulse included in the European guidelines. I think on this call you also talked about maybe nine new papers that are out there. Is there anything that we should be on the lookout for in 2021, opportunities with additional guidelines, maybe even something here in the U.S. or other critical papers that you expect on the come that could help drive, you know, greater adoption of G6?

21:46 Well, there's been a steady stream of papers at the various glaucoma-focused meetings. You know, some relatively large samples. I think one quarter last year we highlighted a 400-patient study by a group from Toronto or led by a group from Toronto and those are the kinds of papers that have been coming out. I think the continued publication of evidence on the more moderate states' patients, publications around experience with dosing profiles and the mechanics of procedures and outcomes associated with that, those are the kind of things that investigators are working on right now and One of the things that we want to focus on is expanding our support of appropriate clinical studies to give the medical community just a greater confidence in particular subsets of patient types, specifically moderates and looking at concomitant procedures with cataract.

22:57 There's been some publications of that, but a broader set of experience would be desirable. So we look for those kinds of things through the course of 2021.

23:05 All right. Very helpful. Thanks, guys. I'll take the rest off the line. Thanks for your time. Thank you. Thank you. I'm showing no further questions at this time. I'll have to turn the call back over to David Bruce for any closing remarks.

23:20 Thank you, Operator. That concludes our conference call for today. Thank you for joining, and we'll look forward to updating you in future quarters. Thank you. Ladies and gentlemen, this does conclude today's conference. Thank you all for participating in Renown Disconnect.

23:35 Have a great day.

Follow IRIDEX Corporation into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

David Bruce

Chief Executive Officer

John Block

Analyst

Fwad Ahmad

Interim Chief Financial Officer

Leigh Salvo

Investor Relations

More from IRIDEX Corporation